Table 4.
Clinical Outcomes in Patients With Multiple Myeloma Treated With Bisphosphonate Therapy
| Study | Year | Patient Population | Treatment | Overall Survival |
Progression-Free Survival |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Median (months) | HR | 95% CI | P | Median (months) | HR | 95% CI | P | ||||
| Morgan et al (MRC Myeloma IX)34 | 2010 | Newly diagnosed patients with MM | ZOL (n = 981) | 50 | 0.842 | 0.74 to 0.96 | .012 | 19.5 | 0.883 | 0.80 to 0.98 | .018 |
| CLO (n = 979) | 44.5 | 17.5 | |||||||||
| Berenson et al28 | 1998 | Patients with MM who received second-line antimyeloma chemotherapy (stratum two) | PAM (n = 66) | 21 | N/A | .081 | N/A | N/A | N/A | ||
| PLA (n = 65) | 14 | ||||||||||
| McCloskey et al25 | 2001 | Patients with no vertebral fractures at presentation | CLO (n = 73) | 59 | 0.62 | 0.43 to 0.87 | .004 | N/A | N/A | N/A | |
| PLA (n = 80) | 37 | ||||||||||
Abbreviations: CLO, clodronate; HR, hazard ratio; MM, multiple myeloma; MRC, Medical Research Council; N/A, not applicable; PAM, pamidronate; PLA, placebo; ZOL, zoledronic acid.